Aviceda Therapeutics Raises Upsized $207.5 Million in Series C ...

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials

businesswire.com

Aviceda Therapeutics Completes $207.5 Million Series C Financing …

3 weeks from now

Jan 9, 2025  · Aviceda Therapeutics secured $207.5 million in Series C funding to support AVD-104 trials for geographic atrophy. The phase 2b/3 study will compare AVD-104's safety and …

ophthalmologytimes.com

Aviceda Raises $207.5 Million In Series C Funding To Advance

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release. Omega Funds and …

healio.com

Aviceda Raises $207.5m For Eye Drug, And Other Financings

3 weeks from now

Jan 30, 2025  · Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) …

pharmaphorum.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials. ... today …

biospace.com

Aviceda Raises $207.5M For AVD-104 Phase 3 Trial | OBN

3 weeks from now

Jan 9, 2025  · Aviceda Therapeutics Secures $207.5 Million to Advance AVD-104 for Geographic Atrophy. January 09, 2025 . Aviceda Therapeutics has successfully closed a $207.5 million …

ophthalmologybreakingnews.com

Aviceda Therapeutics Raises $207.5 Million To Advance Lead …

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for …

eyewire.news

Aviceda Therapeutics Raises Upsized $207.5M In Series C Financing

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators, raised $207.5M in Series C …

finsmes.com

Aviceda Therapeutics: $207.5 Million (Series C) Raised To Develop …

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity Ligands of …

pulse2.com

Aviceda Raises $207M Series C To Take Geographic Atrophy Drug …

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease …

fiercebiotech.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials Business Wire …

yahoo.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ... today …

enavatesciences.com

Aviceda Therapeutics Raises $207.5 Mn In Series C Financing Round

3 weeks from now

Jan 9, 2025  · Aviceda Therapeutics, a private, clinical-stage biotech company announced the closing of a $207.5 million Series C financing.

startuprise.io

Foley Represents TCGX And Omega Funds In $207.5M Series C …

3 weeks from now

Jan 9, 2025  · Foley & Lardner LLP represented TCG Crossover (TCGX) and Omega Funds as lead investors in the $207.5 million Series C financing for Aviceda Therapeutics (Aviceda). …

foley.com

Aviceda Therapeutics Completes $207.5 Million Series C Financing …

3 weeks from now

Aviceda Therapeutics secured $207.5 million in Series C funding to support AVD-104 trials for geographic atrophy. The phase 2b/3 study will compare AVD-104 Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment - NewsBreak

newsbreak.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity Ligands of …

financialcontent.com

Aviceda Therapeutics Secures $207.5M For AVD-104 Clinical Trials

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics closes $207.5 million Series C financing for ongoing clinical trials of AVD-104, a potential treatment for geographic atrophy. AI-assisted, human-published Latest headlines

venturecapital.com

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Jan 7, 2025  · Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy …

yahoo.com

Aviceda Therapeutics Raises $207.5 Million In Series C

3 weeks from now

Jan 7, 2025  · CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a …

citybiz.co

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Paris, France, January 7 th, 2025 – Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the …

kauppalehti.fi

Series C - Aviceda Therapeutics - 2025-01-07 - Crunchbase

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics raised $207500000 on 2025-01-07 in Series C. Start Free Trial . Chrome Extension

crunchbase.com

AdvanCell Successfully Completes An Oversubscribed US$112M …

3 weeks from now

3 days ago  · SYDNEY--(BUSINESS WIRE)-- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful …

nasdaq.com